-
1
-
-
0028939781
-
Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement
-
COI: 1:STN:280:DyaK2M3gslShsQ%3D%3D, PID: 7534919
-
Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, et al. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate. 1995;26:164–8.
-
(1995)
Prostate.
, vol.26
, pp. 164-168
-
-
Murphy, G.P.1
Holmes, E.H.2
Boynton, A.L.3
Kenny, G.M.4
Ostenson, R.C.5
Erickson, S.J.6
-
2
-
-
0031834798
-
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer
-
COI: 1:STN:280:DyaK1c3nt1Sqtg%3D%3D, PID: 9610563
-
Murphy GP, Kenny GM, Ragde H, Wolfert RL, Boynton AL, Holmes EH, et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology. 1998;51:89–97.
-
(1998)
Urology.
, vol.51
, pp. 89-97
-
-
Murphy, G.P.1
Kenny, G.M.2
Ragde, H.3
Wolfert, R.L.4
Boynton, A.L.5
Holmes, E.H.6
-
3
-
-
0032845060
-
Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
-
COI: 1:CAS:528:DyaK1cXnsFChtLk%3D
-
Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urology. 1998;160:2396–401.
-
(1998)
J Urology.
, vol.160
, pp. 2396-2401
-
-
Murphy, G.P.1
Greene, T.G.2
Tino, W.T.3
Boynton, A.L.4
Holmes, E.H.5
-
4
-
-
0032400798
-
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen
-
COI: 1:STN:280:DyaK1M%2FlsValsg%3D%3D, PID: 9840525
-
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259–69.
-
(1998)
Cancer.
, vol.83
, pp. 2259-2269
-
-
Murphy, G.P.1
Elgamal, A.A.2
Su, S.L.3
Bostwick, D.G.4
Holmes, E.H.5
-
5
-
-
0032188742
-
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
-
COI: 1:STN:280:DyaK1cvjsVSnug%3D%3D, PID: 9763084
-
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–40.
-
(1998)
Urology.
, vol.52
, pp. 637-640
-
-
Sweat, S.D.1
Pacelli, A.2
Murphy, G.P.3
Bostwick, D.G.4
-
6
-
-
0031042591
-
Prostate-specific membrane antigen expression in normal and malignant human tissues
-
COI: 1:STN:280:DyaK1M%2FjsFamtA%3D%3D, PID: 9815541
-
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
-
(1997)
Clin Cancer Res.
, vol.3
, pp. 81-85
-
-
Silver, D.A.1
Pellicer, I.2
Fair, W.R.3
Heston, W.D.4
Cordon-Cardo, C.5
-
7
-
-
70449532104
-
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers
-
COI: 1:CAS:528:DC%2BD1MXhsVens77I, PID: 19716160
-
Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009;40:1754–61.
-
(2009)
Hum Pathol.
, vol.40
, pp. 1754-1761
-
-
Haffner, M.C.1
Kronberger, I.E.2
Ross, J.S.3
Sheehan, C.E.4
Zitt, M.5
Muhlmann, G.6
-
8
-
-
84864549393
-
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity
-
COI: 1:CAS:528:DC%2BC38XhtFCrsLrK, PID: 22460809
-
Haffner MC, Laimer J, Chaux A, Schafer G, Obrist P, Brunner A, et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol. 2012;25:1079–85.
-
(2012)
Mod Pathol.
, vol.25
, pp. 1079-1085
-
-
Haffner, M.C.1
Laimer, J.2
Chaux, A.3
Schafer, G.4
Obrist, P.5
Brunner, A.6
-
9
-
-
0030866116
-
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
-
COI: 1:CAS:528:DyaK2sXlvFensbo%3D, PID: 9288760
-
Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–34.
-
(1997)
Cancer Res.
, vol.57
, pp. 3629-3634
-
-
Liu, H.1
Moy, P.2
Kim, S.3
Xia, Y.4
Rajasekaran, A.5
Navarro, V.6
-
10
-
-
0032737848
-
Prostate-specific membrane antigen: much more than a prostate cancer marker
-
COI: 1:CAS:528:DyaK1MXnsVehurw%3D, PID: 10851338
-
Chang SS, Gaudin PB, Reuter VE, O’Keefe DS, Bacich DJ, Heston WD. Prostate-specific membrane antigen: much more than a prostate cancer marker. Mol Urol. 1999;3:313–20.
-
(1999)
Mol Urol.
, vol.3
, pp. 313-320
-
-
Chang, S.S.1
Gaudin, P.B.2
Reuter, V.E.3
O’Keefe, D.S.4
Bacich, D.J.5
Heston, W.D.6
-
11
-
-
0032740888
-
Prostate-specific membrane antigen is produced in tumor-associated neovasculature
-
COI: 1:CAS:528:DyaK1MXntlGltLw%3D, PID: 10537328
-
Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.
-
(1999)
Clin Cancer Res.
, vol.5
, pp. 2674-2681
-
-
Chang, S.S.1
O’Keefe, D.S.2
Bacich, D.J.3
Reuter, V.E.4
Heston, W.D.5
Gaudin, P.B.6
-
12
-
-
34548462642
-
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms
-
PID: 17826525
-
Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.
-
(2007)
Urology.
, vol.70
, pp. 385-390
-
-
Baccala, A.1
Sercia, L.2
Li, J.3
Heston, W.4
Zhou, M.5
-
13
-
-
84929010421
-
-
J Clin Oncol, New Orleans, LA
-
Ross JS, Schenkein D, Webb I, Gray G, Deeds J, Meyer R, et al. Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers. ASCO Annual Meeting Proceedings (Post-Meeting Edition). New Orleans, LA: J Clin Oncol; 2004. p. 3110.
-
(2004)
Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers. ASCO Annual Meeting Proceedings (Post-Meeting Edition)
, pp. 3110
-
-
Ross, J.S.1
Schenkein, D.2
Webb, I.3
Gray, G.4
Deeds, J.5
Meyer, R.6
-
14
-
-
0038315416
-
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor
-
COI: 1:CAS:528:DC%2BD3sXjtlKnsbw%3D
-
Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nuc Med. 2003;44:610–7.
-
(2003)
J Nuc Med.
, vol.44
, pp. 610-617
-
-
Smith-Jones, P.M.1
Vallabhajosula, S.2
Navarro, V.3
Bastidas, D.4
Goldsmith, S.J.5
Bander, N.H.6
-
15
-
-
4243489788
-
Phase 1 clinical trial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer [abstract 1872]
-
Bander NH, Nanus D, Bremer S. Phase 1 clinical trial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer [abstract 1872]. Proc Am Soc Clin Oncol. 2000;19:477a.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
, pp. 477
-
-
Bander, N.H.1
Nanus, D.2
Bremer, S.3
-
16
-
-
0142030952
-
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen
-
COI: 1:CAS:528:DC%2BD3sXpt1Gksb0%3D, PID: 14571414
-
Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003;30:667–76.
-
(2003)
Semin Oncol.
, vol.30
, pp. 667-676
-
-
Bander, N.H.1
Nanus, D.M.2
Milowsky, M.I.3
Kostakoglu, L.4
Vallabahajosula, S.5
Goldsmith, S.J.6
-
17
-
-
12444285340
-
Radiolabeled humanized monoclonal antibodies to PSMA: phase I dose escalation studies with In-111-DOTA-hu-J591
-
Vallabhajosula S, Kuji I, Kostakoglu L, Smith-Jones PM, Zoe H, Bander NH, et al. Radiolabeled humanized monoclonal antibodies to PSMA: phase I dose escalation studies with In-111-DOTA-hu-J591. J Nucl Med. 2001;42:122P–3.
-
(2001)
J Nucl Med.
, vol.42
, pp. 122-123
-
-
Vallabhajosula, S.1
Kuji, I.2
Kostakoglu, L.3
Smith-Jones, P.M.4
Zoe, H.5
Bander, N.H.6
-
18
-
-
34249101981
-
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
-
COI: 1:CAS:528:DC%2BD2sXkslOhur0%3D, PID: 17473203
-
Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O’Donoghue JA, Nacca A, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. 2007;13(9):2707–13.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.9
, pp. 2707-2713
-
-
Morris, M.J.1
Pandit-Taskar, N.2
Divgi, C.R.3
Bender, S.4
O’Donoghue, J.A.5
Nacca, A.6
-
19
-
-
85001075549
-
Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced solid tumors
-
Morris MJ, Divgi C, Kelly WK, Slovin S, Solit D, Shaffer D, et al. Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced solid tumors. Proc Am Assn Cancer Res Ann Mtg. 2003;44:803.
-
(2003)
Proc Am Assn Cancer Res Ann Mtg.
, vol.44
, pp. 803
-
-
Morris, M.J.1
Divgi, C.2
Kelly, W.K.3
Slovin, S.4
Solit, D.5
Shaffer, D.6
-
20
-
-
46749104779
-
Antibody mass escalation study in patients with castration-resistant prostate cancer using (111)In-J591: lesion detectability and dosimetric projections for (90)Y radioimmunotherapy
-
PID: 18552139
-
Pandit-Taskar N, O’Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using (111)In-J591: lesion detectability and dosimetric projections for (90)Y radioimmunotherapy. J Nucl Med. 2008;49(7):1066–74.
-
(2008)
J Nucl Med
, vol.49
, Issue.7
, pp. 1066-1074
-
-
Pandit-Taskar, N.1
O’Donoghue, J.A.2
Morris, M.J.3
Wills, E.A.4
Schwartz, L.H.5
Gonen, M.6
-
21
-
-
27144544111
-
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific-membrane antigen antibody J591 for castrate metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BD2MXhtFartbvK, PID: 16243819
-
Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific-membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005;11:7454–61.
-
(2005)
Clin Cancer Res.
, vol.11
, pp. 7454-7461
-
-
Morris, M.J.1
Divgi, C.R.2
Pandit-Taskar, N.3
Batraki, M.4
Warren, N.5
Nacca, A.6
-
22
-
-
33947529429
-
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
-
COI: 1:CAS:528:DC%2BD2sXivF2mtLo%3D, PID: 17290063
-
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.
-
(2007)
J Clin Oncol
, vol.25
, Issue.5
, pp. 540-547
-
-
Milowsky, M.I.1
Nanus, D.M.2
Kostakoglu, L.3
Sheehan, C.E.4
Vallabhajosula, S.5
Goldsmith, S.J.6
-
23
-
-
0031940813
-
Simulation, analysis, and modeling software for tracer and pharmacokinetic studies
-
COI: 1:CAS:528:DyaK1cXitlygurg%3D, PID: 9550550
-
Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. Simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.
-
(1998)
Metabolism.
, vol.47
, pp. 484-492
-
-
Barrett, P.H.1
Bell, B.M.2
Cobelli, C.3
Golde, H.4
Schumitzky, A.5
Vicini, P.6
-
24
-
-
0035186450
-
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient
-
COI: 1:STN:280:DC%2BD3Mnntlyjsw%3D%3D, PID: 11719674
-
Gonen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001;221:763–7.
-
(2001)
Radiology.
, vol.221
, pp. 763-767
-
-
Gonen, M.1
Panageas, K.S.2
Larson, S.M.3
-
25
-
-
84919950141
-
(89)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BC2cXhsVSisbrM
-
Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. (89)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nuc Med Mol Imag. 2014;41:2093–105.
-
(2014)
Eur J Nuc Med Mol Imag
, vol.41
, pp. 2093-2105
-
-
Pandit-Taskar, N.1
O’Donoghue, J.A.2
Beylergil, V.3
Lyashchenko, S.4
Ruan, S.5
Solomon, S.B.6
|